Experimental gene therapy tested for rare muscular dystrophy

NCT ID NCT06747273

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested a gene therapy called SRP-9004 in just 4 people with limb girdle muscular dystrophy type 2D/R3, a rare muscle-weakening disease. The main goal was to check safety, not effectiveness. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SRP-9004 (a gene therapy given by IV infusion)

What this could lead to

If successful, this could point toward a treatment that slows or stops muscle damage in people with this rare form of muscular dystrophy.

What could go wrong

This was a very early (phase 1b) trial with only 4 participants, and it was terminated early. The therapy may not work or could cause side effects. Results are not yet known.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIMB GIRDLE MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal recessive limb-girdle muscular dystrophy type 2D limb-girdle muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Hospital of the King's Daughters

    Norfolk, Virginia, 23510, United States

  • Nationwide Children's Hospital

    Columbus, Ohio, 43205, United States